Sartorius has introduced an integrated system for producing and quality-controlling autologous cell therapies that addresses critical manufacturing bottlenecks limiting patient access to transformative treatments. The modular Eveo Cell Therapy Platform enables automated, multi-parallel intensified production that could reduce manufacturing costs by approximately 90 percent in CAR-T processes while increasing output up to fourfold within existing cleanroom space.
Cell therapies represent a medical breakthrough but remain inaccessible to most patients due to complex, capacity-constrained manufacturing that drives up costs. According to Rene Faber, member of the Executive Board at Sartorius, the company's integrated platform tackles these structural bottlenecks by combining raw materials, production equipment, software and quality control assays into a scalable system. This approach enables customers to expand output, significantly reduce cost per dose, and shorten vein-to-vein time for patients awaiting treatment.
Traditional manufacturing models for autologous cell therapies require centralized, purpose-built facilities with substantial greenfield investment, staff recruitment, training and multi-year build-up phases. Approximately 60 percent of regulatory disruptions in cell therapy production stem from manufacturing and process-related issues. The Eveo platform addresses these challenges by integrating cell selection, activation, gene modification, expansion, wash and concentration, and final formulation into a closed system using various Sartorius solutions from critical raw materials to bioreactors and separation technologies.
The system's compact design supports implementation in existing facilities with current staff, allows operation in lower-classification environments, and accommodates both centralized and decentralized manufacturing models. In a successful pilot project with cell therapy CDMO ElevateBio, the platform performed according to design expectations, demonstrating real-world applicability. Due to its multi-parallel configuration, a single operator can process eight patient batches simultaneously in the cleanroom space traditionally needed for two batches.
Assuming a manufacturing time of approximately seven days per batch and 50 production weeks annually, Eveo enables production of more than 350 doses per year in a footprint that currently yields roughly 100 doses—representing an almost fourfold increase. Quality control represents another major bottleneck in cell therapy production and release, which the Eveo platform addresses through Sartorius' capabilities in live cell imaging and high throughput flow cytometry included in the system.
Sartorius plans to begin accepting orders for the Eveo Cell Therapy Platform in September 2026, with initial deliveries expected in 2027. ElevateBio will receive access to one of the first Eveo platforms as a preferred partner for use with its manufacturing customers. More information about the platform is available at https://www.sartorius.com/en/pr/eveo-cell-therapy-platform.
